Spyre Therapeutics (SYRE) Interest & Investment Income (2015 - 2026)
Spyre Therapeutics (SYRE) posted Interest & Investment Income of $7.0 million for Q1 2026, down 2.02% on a QoQ basis from $7.1 million in Q4 2025, and up 7.73% year-over-year from $6.5 million in Q1 2025.
Spyre Therapeutics (SYRE) Interest & Investment Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- Quarterly Interest & Investment Income rose 7.73% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (up 11.95% YoY) and the FY2025 annual result came in at $24.9 million, up 16.77% from the prior year.
- Interest & Investment Income was $7.0 million for Q1 2026 at Spyre Therapeutics, down from $7.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.1 million in Q4 2025 and bottomed at -$681000.0 in Q1 2024.
- A 5-year average of $2.5 million and a median of $420000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 1105.88% — and 2024, when it sank 19300.0%.
- Spyre Therapeutics' Interest & Investment Income stood at $410000.0 in 2022, then jumped by 906.34% to $4.1 million in 2023, then soared by 39.99% to $5.8 million in 2024, then increased by 23.6% to $7.1 million in 2025, then retreated by 2.02% to $7.0 million in 2026.
- Business Quant data shows SYRE's Interest & Investment Income at $7.0 million in Q1 2026, $7.1 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Spyre Therapeutics | 259.59 Mn | 259.59 Mn | - | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 7.14 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | -192,000.00 |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Sep 30, 2024 | 5.18 Mn |
| Jun 30, 2024 | -194,000.00 |
| Mar 31, 2024 | -681,000.00 |
| Dec 31, 2023 | 4.13 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | 420,000.00 |
| Dec 31, 2022 | 410,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Mar 31, 2022 | -120,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | 36,000.00 |
| Jun 30, 2021 | 19,000.00 |